References
- Sun SC. The noncanonical NF-κB pathway. Immunol. Rev. 246(1), 125–140 (2012).
- Yang Y, Fang S, Jensen JP, Weissman AM, Ashwell JD. Ubiquitin protein ligase activity of IAPs and their degradation in proteasomes in response to apoptotic stimuli. Science 288(5467), 874–877 (2000).
- Xiao G, Harhaj EW, Sun SC. NF-κB-inducing kinase regulates the processing of NF-κB2 p100. Mol. Cell 7(2), 401–409 (2001).
- Wharry CE, Haines KM, Carroll RG, May MJ. Constitutive non-canonical NFκB signaling in pancreatic cancer cells. Cancer Biol. Ther. 8(16), 1567–1576 (2009).
- Chandler NM, Canete JJ, Callery MP. Increased expression of NF-κB subunits in human pancreatic cancer cells. J. Surg. Res. 118(1), 9–14 (2004).
- Nishina T, Yamaguchi N, Gohda J, Semba K, Inoue J. NIK is involved in constitutive activation of the alternative NF-κB pathway and proliferation of pancreatic cancer cells. Biochem. Biophys. Res. Commun. 388(1), 96–101 (2009).
- Döppler H, Liou GY, Storz P. Downregulation of TRAF2 mediates NIK-induced pancreatic cancer cell proliferation and tumorigenicity. PLoS ONE 8(1), e53676 (2013).
- Schneider G, Saur D, Siveke JT, Fritsch R, Greten FR, Schmid RM. IKKα controls p52/RelB at the skp2 gene promoter to regulate G1- to S-phase progression. EMBO J. 25(16), 3801–3812 (2006).
- Annunziata CM, Davis RE, Demchenko Y et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 12(2), 115–130 (2007).
- Hunter AM, LaCasse EC, Korneluk RG. The inhibitors of apoptosis (IAPs) as cancer targets. Apoptosis 12(9), 1543–1568 (2007).
- Mortier J, Masereel B, Remouchamps C, Ganeff C, Piette J, Frederick R. NF-κB inducing kinase (NIK) inhibitors: identification of new scaffolds using virtual screening. Bioorg. Med. Chem. Lett. 20(15), 4515–4520 (2010).
- de Leon-Boenig G, Bowman KK, Feng JA et al. The crystal structure of the catalytic domain of the NF-κB inducing kinase reveals a narrow but flexible active site. Structure 20(10), 1704–1714 (2012).
- Liu J, Sudom A, Min X et al. Structure of the nuclear factor κB-inducing kinase (NIK) kinase domain reveals a constitutively active conformation. J. Biol. Chem. 287(33), 27326–27334 (2012).
- Zhang T, Hamza A, Cao X et al. A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7(1), 162–170 (2008).
- Qing G, Yan P, Qu Z, Liu H, Xiao G. Hsp90 regulates processing of NF-κ B2 p100 involving protection of NF-κ B-inducing kinase (NIK) from autophagy-mediated degradation. Cell Res. 17(6), 520–530 (2007).
- Hu WH, Mo XM, Walters WM, Brambilla R, Bethea JR. TNAP, a novel repressor of NF-κB-inducing kinase, suppresses NF-κB activation. J. Biol. Chem. 279(34), 35975–35983 (2004).
- Nawrocki ST, Carew JS, Pino MS et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res. 66(7), 3773–3781 (2006).
- Dai Y, Liu M, Tang W et al. Molecularly targeted radiosensitization of human prostate cancer by modulating inhibitor of apoptosis. Clin. Cancer Res. 14(23), 7701–7710 (2008).
- Luqman S, Pezzuto JM. NFκB: a promising target for natural products in cancer chemoprevention. Phytother. Res. 24(7), 949–963 (2010).
- Fendrich V, Chen NM, Neef M et al. The angiotensin-I-converting enzyme inhibitor enalapril and aspirin delay progression of pancreatic intraepithelial neoplasia and cancer formation in a genetically engineered mouse model of pancreatic cancer. Gut 59(5), 630–637 (2010).
- Xu Y, Fang F, St Clair DK, Sompol P, Josson S, St Clair WH. SN52, a novel nuclear factor-κB inhibitor, blocks nuclear import of RelB:p52 dimer and sensitizes prostate cancer cells to ionizing radiation. Mol. Cancer Ther. 7(8), 2367–2376 (2008).
- Gilmore TD, Herscovitch M. Inhibitors of NF-κB signaling: 785 and counting. Oncogene 25(51), 6887–6899 (2006).
- Thu YM, Richmond A. NF-κB inducing kinase: a key regulator in the immune system and in cancer. Cytokine Growth Factor Rev. 21(4), 213–226 (2010).
- Baud V, Karin M. Is NF-κB a good target for cancer therapy? Hopes and pitfalls. Nat. Rev. Drug Discov. 8(1), 33–40 (2009).
Patents
- Flohr S, Naumann T. Pyrazoloisoquinoline derivates for inhibiting NF-κB-inducing kinase. US-6841556-B2 (2005).
- Majid TN, Hopkins C, Pedgrift BL, Collar N, Wirtz-Brugger F, Merrill J. Pyrazoloisoquinoline derivative as kinase inhibitors for the treatment of various disorders. US-7132428-B2 (2006).
- Chen G, Cushing TD, Faulder P et al. Alkynyl alcohols as kinase inhibitors. US2011/0086834-A1 (2009).